Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||Study for Promotion of Health in Recycling Lead - Rationale and design|
|Authors: ||Hara, Azusa|
Staessen, Jan A.
|Issue Date: ||2015|
|Publisher: ||INFORMA HEALTHCARE|
|Citation: ||BLOOD PRESSURE, 24 (3), p. 147-157|
|Abstract: ||Background. The level at which low-level lead exposure produces subclinical adverse health effects in adults remains to be established. Methods. The Study for Promotion of Health in Recycling Lead (SPHERL) will enroll 500 newly hired workers, whose blood lead during 2 years of follow-up is expected to increase from levels less than 2 mu g/dl, as currently observed in the US population, to 20-30 mu g/dl. The main outcome variables to be studied are (i) blood pressure (BP) analyzed as a continuous or categorical variable, both cross-sectionally and longitudinally, and using conventional and ambulatory BP measurement; (ii) indexes of glomerular and tubular renal function, (iii) heart rate variability analyzed in the frequency domain as measure of autonomous sympathetic modulation, (iv) peripheral nerve conductivity velocity, (v) neurocognitive performance, and (vi) quality of life. Expected outcomes. Assuming a 10-fold increase in blood lead, SPHERL will have sufficient statistical power to detect over 2 years a steepening of the age-related rise in systolic BP from 1 to 5 mmHg and a doubling of the age-related decline in the estimated glomerular filtration rate from 3.5 to 7.0 ml/min/1.73 m(2). The longitudinal design of our study complies with the temporality principle of the Bradford-Hill criteria for assessing possible causality between outcomes and exposure. SPHERL will attempt to resolve the apparent contradiction between general population studies showing associations between adverse health effects and low lead exposure with blood lead levels below 5 mu g/dl and studies conducted in occupational cohorts indicating that adverse effects of lead exposure occur at much higher blood lead levels.|
|Notes: ||[Hara, Azusa; Gu, Yu-Mei; Petit, Thibault; Liu, Yan-Ping; Jacobs, Lotte; Zhang, Zhen-Yu; Yang, Wen-Yi; Jin, Yu; Thijs, Lutgarde; Wei, Fang-Fei; Staessen, Jan A.] Univ Leuven, KU Leuven Dept Cardiovasc Sci, Res Unit Hypertens & Cardiovasc Epidemiol, Studies Coordinating Ctr, BE-3000 Leuven, Belgium. [Nawrot, Tim S.] Univ Hasselt, Ctr Environm Sci, Diepenbeek, Belgium. [Staessen, Jan A.] Maastricht Univ, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands. [Staessen, Jan A.] Maastricht Univ, VitaK Res & Dev, NL-6200 MD Maastricht, Netherlands. Correspondence: Jan A. Staessen, Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Box 7001; BE3000 Leuven, Belgium. Tel: + 32 16 34 7104. Fax: + 32 16 34 7106. E-mail: email@example.com; firstname.lastname@example.org|
|ISI #: ||000354191800003|
|Type: ||Journal Contribution|
|Validation: ||ecoom, 2016|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.